

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**山東威高集團醫用高分子製品股份有限公司**  
**Shandong Weigao Group Medical Polymer Company Limited \***

*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1066)**

**SUPPLEMENTAL ANNOUNCEMENT**  
**UNAUDITED RESULTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

Reference is made to the announcement of Shandong Weigao Group Medical Polymer Company Limited dated 29 March 2022 (the “**Announcement**”) in relation to the unaudited results for the year ended 31 December 2021.

The Company would like to provide additional information on the Announcement. The Audit Committee of the Company has reviewed the Group’s unaudited consolidated financial statements for the year ended 31 December 2021.

By Order of the Board

**Shandong Weigao Group Medical Polymer Company Limited**

**Long Jing**

*Chairman*

29 March 2022

Weihai, Shandong Province, the PRC

As at the date of this announcement, the Board Comprises:

Mr. Long Jing (*Executive Director*)

Mr. Cong Rinan (*Executive Director*)

Mr. Lian Xiaoming (*Non-executive Director*)

Mr. Chen Lin (*Non-executive Director*)

Mr. Tang Zhengpeng (*Non-executive Director*)

Mr. Lo Wai Hung (*Independent non-executive Director*)

Mrs. Fu Mingzhong (*Independent non-executive Director*)

Mrs. Wang Jinxia (*Independent non-executive Director*)

\* *For identification purpose only*